(Q35895370)

11 August 2017

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer (English)

1 reference

11 August 2017

1 reference

1 reference

18

1 reference

11 August 2017

19

1 reference

11 August 2017

16

Katherine A Hoadley

1 reference

11 August 2017

10

David B Darr

1 reference

11 August 2017

12

Pei-Fen Kuan

1 reference

11 August 2017

11

Jerry Usary

1 reference

11 August 2017

2

Martin C Whittle

1 reference

11 August 2017

James S Duncan

1

1 reference

11 August 2017

Kazuhiro Nakamura

3

1 reference

11 August 2017

Amy N Abell

4

1 reference

11 August 2017

Alicia A Midland

5

1 reference

11 August 2017

Jon S Zawistowski

6

1 reference

11 August 2017

Nancy L Johnson

7

1 reference

11 August 2017

Deborah A Granger

8

1 reference

11 August 2017

Nicole Vincent Jordan

9

1 reference

11 August 2017

David M Smalley

13

1 reference

11 August 2017

Ben Major

14

1 reference

11 August 2017

Xiaping He

15

1 reference

11 August 2017

Bing Zhou

17

1 reference

11 August 2017

William Y Kim

20

1 reference

11 August 2017

Shawn M Gomez

21

1 reference

11 August 2017

Xin Chen

22

1 reference

11 August 2017

Jian Jin

23

1 reference

11 August 2017

Stephen V Frye

24

1 reference

11 August 2017

H Shelton Earp

25

1 reference

11 August 2017

Lee M Graves

26

1 reference

11 August 2017

Gary L Johnson

27

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 April 2012

1 reference

11 August 2017

1 reference

11 August 2017

149

1 reference

11 August 2017

2

1 reference

11 August 2017

307-321

1 reference

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Large-scale proteomics analysis of the human kinome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

A quantitative analysis of kinase inhibitor selectivity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

The c-myc promoter: still MysterY and challenge

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

The (un)targeted cancer kinome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3328787

10.1016/J.CELL.2012.02.053

24 September 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22500798

1 reference